These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 10637718)

  • 61. [Mechanisms of adhesion of Staphylococci to biomaterials: effect of fusidic acid].
    Drugeon HB; Carpentier E
    Pathol Biol (Paris); 1993 Apr; 41(4):392-8. PubMed ID: 8233641
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Effects of salicylate and related compounds on fusidic acid MICs in Staphylococcus aureus.
    Price CT; O'Brien FG; Shelton BP; Warmington JR; Grubb WB; Gustafson JE
    J Antimicrob Chemother; 1999 Jul; 44(1):57-64. PubMed ID: 10459810
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Observations on high levels of fusidic acid resistant Staphylococcus aureus in Harrogate, North Yorkshire, UK.
    Ravenscroft JC; Layton A; Barnham M
    Clin Exp Dermatol; 2000 Jun; 25(4):327-30. PubMed ID: 10971497
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Fusidic acid: new opportunities with an old antibiotic.
    Anderson JD
    Can Med Assoc J; 1980 Apr; 122(7):765-9. PubMed ID: 6988070
    [TBL] [Abstract][Full Text] [Related]  

  • 65. The effect of dicloxacillin and fusidic acid on the extracellular and intracellular killing of Staphylococcus aureus.
    Nielsen SL; Black FT
    J Antimicrob Chemother; 1998 Aug; 42(2):221-6. PubMed ID: 9738840
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Use of antimicrobial susceptibility testing for epidemiology and the selection of oral, parenteral and topical regimens for control of CAPD-associated Staphylococcus aureus infection.
    Pignatari A; Jones RN; Barrett MR; Sesso R; Leme I; Pfaller MA
    J Chemother; 1991 Apr; 3(2):108-16. PubMed ID: 1651997
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Risk factors and evolution of ventilator-associated pneumonia by Staphylococcus aureus sensitive or resistant to oxacillin in patients at the intensive care unit of a Brazilian university hospital.
    Moreira MR; Cardoso RL; Almeida AB; Gontijo Filho PP
    Braz J Infect Dis; 2008 Dec; 12(6):499-503. PubMed ID: 19287838
    [TBL] [Abstract][Full Text] [Related]  

  • 68. MIC determination of fusidic acid and of ciprofloxacin using multidisk diffusion tests.
    Kronvall G
    Clin Microbiol Infect; 2000 Sep; 6(9):483-9. PubMed ID: 11168182
    [TBL] [Abstract][Full Text] [Related]  

  • 69. [Neutropenia during treatment with fusidic acid: analysis of 5 cases].
    Vial T; Gontier D; Pinède L; Cance P; Pofilet C; Evreux JC
    Therapie; 1995; 50(5):447-50. PubMed ID: 8571283
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Concentration and bactericidal activity of fusidic acid and cloxacillin in serum and synovial fluid.
    Somekh E; Golan T; Tanay A; Poch F; Dan M
    J Antimicrob Chemother; 1999 Apr; 43(4):593-6. PubMed ID: 10350394
    [TBL] [Abstract][Full Text] [Related]  

  • 71. [Impetigo in French Guyana. A clinical, bacteriological, toxicological and sensitivity to antibiotics study].
    Couppié P; Sainte-Marie D; Prévost G; Gravet A; Clyti E; Moreau B; Monteil H; Pradinaud R
    Ann Dermatol Venereol; 1998 Oct; 125(10):688-93. PubMed ID: 9835957
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Characterization of global patterns and the genetics of fusidic acid resistance.
    Farrell DJ; Castanheira M; Chopra I
    Clin Infect Dis; 2011 Jun; 52 Suppl 7():S487-92. PubMed ID: 21546625
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Mechanisms of resistance to fusidic acid in Staphylococcus aureus.
    Chopra I
    J Gen Microbiol; 1976 Oct; 96(2):229-38. PubMed ID: 993776
    [TBL] [Abstract][Full Text] [Related]  

  • 74. [High incidence of oxacillin-resistant Staphylococcus aureus in a general hospital].
    Ronchetto F; Pistono PG; Guasco C
    Recenti Prog Med; 1995 Nov; 86(11):463. PubMed ID: 8539482
    [No Abstract]   [Full Text] [Related]  

  • 75. Fusidic-acid use and resistance.
    Livermore D; James D; Duckworth G; Stephens P
    Lancet; 2002 Sep; 360(9335):806. PubMed ID: 12241858
    [No Abstract]   [Full Text] [Related]  

  • 76. Clinical relevance of resistance to fusidic acid in Staphylococcus aureus.
    Shanson DC
    J Antimicrob Chemother; 1990 Feb; 25 Suppl B():15-21. PubMed ID: 2179202
    [TBL] [Abstract][Full Text] [Related]  

  • 77. The postantibiotic effect of fusidic acid against gram-positive bacteria.
    Munckhof WJ; Turnidge JD
    J Antimicrob Chemother; 1997 Sep; 40(3):433-6. PubMed ID: 9338499
    [TBL] [Abstract][Full Text] [Related]  

  • 78. In vitro screening antibacterial activity of Bidens pilosa Linné and Annona crassiflora Mart. against oxacillin resistant Staphylococcus aureus (ORSA) from the aerial environment at the dental clinic.
    Silva JJ; Cerdeira CD; Chavasco JM; Cintra AB; Silva CB; Mendonça AN; Ishikawa T; Boriollo MF; Chavasco JK
    Rev Inst Med Trop Sao Paulo; 2014; 56(4):333-40. PubMed ID: 25076435
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Topical Fucidin.
    Dealler S; Fraser AK
    J R Coll Gen Pract; 1986 Mar; 36(284):136. PubMed ID: 3712354
    [No Abstract]   [Full Text] [Related]  

  • 80. High levels of fusidic acid-resistant Staphylococcus aureus in dermatology patients.
    Shah M; Mohanraj M
    Br J Dermatol; 2003 May; 148(5):1018-20. PubMed ID: 12786835
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.